Christophe Moreno
Université libre de Bruxelles
281 Papers
1.9K Citations
Christophe Moreno is an academic researcher from Université libre de Bruxelles. The author has contributed to research in topics: Medicine & Hepatitis C. The author has an hindex of 53, co-authored 259 publications. Previous affiliations of Christophe Moreno include Free University of Brussels & University of Toronto.
Chat about Author
Papers
Endoscopic duodenal mucosal resurfacing for nonalcoholic steatohepatitis (NASH): a pilot study.
Alia Hadefi,Laurine Verset,Martina Pezzullo,Nicolas Rosewick,Delphine Degré,Thierry Gustot,Christophe Moreno,Jacques Devière,Eric Trepo +8 more
TL;DR: Duodenal mucosal resurfacing (DMR) has been associated with improvement in glycaemic parameters and liver function tests (LFTs) in type 2 diabetes as discussed by the authors.
Sofosbuvir in Combination with Simeprevir +/- Ribavirin in Genotype 4 Hepatitis C Patients with Advanced Fibrosis or Cirrhosis: A Real-World Experience from Belgium.
Delphine Degré,Thomas Sersté,L Lasser,Jean Delwaide,Peter Stärkel,Wim Laleman,Philippe Langlet,Hendrik Reynaert,Suzanne Bourgeois,Thomas Vanwolleghem,Sergio Negrin Dastis,Thierry Gustot,Anja Geerts,Christophe Van Steenkiste,Chantal de Galocsy,Antonia Lepida,Hans Orlent,Christophe Moreno +17 more
TL;DR: Sofosbuvir in combination with simeprevir +/- ribavirin in GT 4 HCV patients with advanced fibrosis achieved high SVR12 rates and was well tolerated and no patient died or discontinued treatment due to adverse events.
Hepatitis B virus and hepatitis C virus infections in Belgium: similarities and differences in epidemics and initial management
Bénédicte De Vroey,Christophe Moreno,Wim Laleman,Marc Van Gossum,Isabelle Colle,Chantal de Galocsy,Philippe Langlet,Geert Robaeys,Hans Orlent,Peter Michielsen,Jean Delwaide,Hendrik Reynaert,F D'Heygere,D. Sprengers,Suzanne Bourgeois,C Assene,Bertrand Vos,Réginald Brenard,Michael Adler,Jean Henrion,Pierre Deltenre +20 more
TL;DR: HBV and HCV screening policies should be targeted toward immigrants and intravenous drug users, respectively and guidelines recommending systematic search for viral replication should be reinforced in HBV patients.
12
12 Weeks of a Ribavirin-Free Sofosbuvir and Nonstructural Protein 5A Inhibitor Regimen Is Enough to Treat Recurrence of Hepatitis C After Liver Transplantation
Pauline Houssel-Debry,Audrey Coilly,Claire Fougerou-Leurent,Caroline Jezequel,Christophe Duvoux,Victor de Lédinghen,Sylvie Radenne,Nassim Kamar,Vincent Leroy,Vincent Di Martino,Louis d’Alteroche,Valérie Canva,Filomena Conti,Jérôme Dumortier,H. Montialoux,Pascal Lebray,Danielle Botta-Fridlund,Albert Tran,Christophe Moreno,Christine Silvain,Camille Besch,P. Perré,Claire Francoz,Armando Abergel,François Habersetzer,Maryline Debette-Gratien,Carole Cagnot,Alpha Diallo,Stéphane Chevaliez,Emilie Rossignol,Aurelie Veislinger,Jean-Charles Duclos-Vallée,Georges-Philippe Pageaux +32 more
TL;DR: SOF + NS5A inhibitors without RBV for 12 weeks constituted reliable therapy for recurrent HCV post‐LT with an excellent SVR12 whatever the fibrosis stage, HCV genotype, and previous HCV treatment.
12
Ombitasvir/paritaprevir/ritonavir plus ribavirin for 24 weeks in patients with HCV GT4 and compensated cirrhosis (AGATE-I Part II).
Tarik Asselah,Negar N. Alami,Christophe Moreno,Stanislas Pol,Stanislas Pol,Stylianos Karatapanis,Michael Gschwantler,Yves Horsmans,Ioannis S. Elefsiniotis,Dominique Larrey,Carlo Ferrari,Mario Rizzetto,Alessandra Orlandini,Jose Luis Calleja,Savino Bruno,Gretja Schnell,Roula B. Qaqish,Rebecca Redman,Tami Pilot-Matias,Sarah Kopecky-Bromberg,Yao Yu,N. Mobashery +21 more
- 01 Mar 2019
TL;DR: The trial was extended to include a 24‐week treatment arm to fully assess treatment duration in patients with chronic hepatitis C genotype 4 infection and compensated cirrhosis.
12